Literature DB >> 25202977

Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders.

Alexander J Gill, Colleen E Kovacsics, Stephanie A Cross, Patricia J Vance, Lorraine L Kolson, Kelly L Jordan-Sciutto, Benjamin B Gelman, Dennis L Kolson.   

Abstract

Heme oxygenase-1 (HO-1) is an inducible, detoxifying enzyme that is critical for limiting oxidative stress, inflammation, and cellular injury within the CNS and other tissues. Here, we demonstrate a deficiency of HO-1 expression in the brains of HIV-infected individuals. This HO-1 deficiency correlated with cognitive dysfunction, HIV replication in the CNS, and neuroimmune activation. In vitro analysis of HO-1 expression in HIV-infected macrophages, a primary CNS HIV reservoir along with microglia, demonstrated a decrease in HO-1 as HIV replication increased. HO-1 deficiency correlated with increased culture supernatant glutamate and neurotoxicity, suggesting a link among HIV infection, macrophage HO-1 deficiency, and neurodegeneration. HO-1 siRNA knockdown and HO enzymatic inhibition in HIV-infected macrophages increased supernatant glutamate and neurotoxicity. In contrast, increasing HO-1 expression through siRNA derepression or with nonselective pharmacologic inducers, including the CNS-penetrating drug dimethyl fumarate (DMF), decreased supernatant glutamate and neurotoxicity. Furthermore, IFN-γ, which is increased in CNS HIV infection, reduced HO-1 expression in cultured human astrocytes and macrophages. These findings indicate that HO-1 is a protective host factor against HIV-mediated neurodegeneration and suggest that HO-1 deficiency contributes to this degeneration. Furthermore, these results suggest that HO-1 induction in the CNS of HIV-infected patients on antiretroviral therapy could potentially protect against neurodegeneration and associated cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25202977      PMCID: PMC4191052          DOI: 10.1172/JCI72279

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice.

Authors:  N Panahian; M Yoshiura; M D Maines
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

2.  CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin.

Authors:  Dominik J Schaer; Christian A Schaer; Paul W Buehler; Robert A Boykins; Gabriele Schoedon; Abdu I Alayash; Andreas Schaffner
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

3.  Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury.

Authors:  L E Otterbein; J K Kolls; L L Mantell; J L Cook; J Alam; A M Choi
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  Suppression of heme oxygenase-1 mRNA expression by interferon-gamma in human glioblastoma cells.

Authors:  K Takahashi; M Nakayama; K Takeda; H Fujia; S Shibahara
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

5.  Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes.

Authors:  Lauren A O'Donnell; Arpita Agrawal; Kelly L Jordan-Sciutto; Marc A Dichter; David R Lynch; Dennis L Kolson
Journal:  J Neurosci       Date:  2006-01-18       Impact factor: 6.167

6.  Neural heme oxygenase-1 expression in idiopathic Parkinson's disease.

Authors:  H M Schipper; A Liberman; E G Stopa
Journal:  Exp Neurol       Date:  1998-03       Impact factor: 5.330

7.  CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE).

Authors:  Eleanor S Roberts; Eleizer Masliah; Howard S Fox
Journal:  J Neuropathol Exp Neurol       Date:  2004-12       Impact factor: 3.685

8.  Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation.

Authors:  S L Camhi; J Alam; L Otterbein; S L Sylvester; A M Choi
Journal:  Am J Respir Cell Mol Biol       Date:  1995-10       Impact factor: 6.914

Review 9.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 10.  Heme oxygenase expression in human central nervous system disorders.

Authors:  Hyman M Schipper
Journal:  Free Radic Biol Med       Date:  2004-12-15       Impact factor: 7.376

View more
  41 in total

1.  SIV-Induced Immune Activation and Metabolic Alterations in the Dorsal Root Ganglia During Acute Infection.

Authors:  Lisa M Mangus; Rachel L Weinberg; Audrey C Knight; Suzanne E Queen; Robert J Adams; Joseph L Mankowski
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

2.  CROI 2015: Neurologic Complications of HIV Infection.

Authors:  Serena S Spudich; Beau M Ances
Journal:  Top Antivir Med       Date:  2015 Mar-Apr

3.  White Matter Abnormalities Linked to Interferon, Stress Response, and Energy Metabolism Gene Expression Changes in Older HIV-Positive Patients on Antiretroviral Therapy.

Authors:  Isaac H Solomon; Sukrutha Chettimada; Vikas Misra; David R Lorenz; Robert J Gorelick; Benjamin B Gelman; Susan Morgello; Dana Gabuzda
Journal:  Mol Neurobiol       Date:  2019-11-05       Impact factor: 5.590

4.  Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

Authors:  Brigid K Jensen; Hubert Monnerie; Maggie V Mannell; Patrick J Gannon; Cagla Akay Espinoza; Michelle A Erickson; Annadora J Bruce-Keller; Benjamin B Gelman; Lisa A Briand; R Christopher Pierce; Kelly L Jordan-Sciutto; Judith B Grinspan
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

5.  Neurologic Complications in Persons With HIV Infection in the Era of Antiretroviral Therapy.

Authors:  Dennis Kolson
Journal:  Top Antivir Med       Date:  2017 Jul/Aug

6.  Degradation of heme oxygenase-1 by the immunoproteasome in astrocytes: A potential interferon-γ-dependent mechanism contributing to HIV neuropathogenesis.

Authors:  Colleen E Kovacsics; Alexander J Gill; Surendra S Ambegaokar; Benjamin B Gelman; Dennis L Kolson
Journal:  Glia       Date:  2017-05-22       Impact factor: 7.452

7.  MUTYH promotes oxidative microglial activation and inherited retinal degeneration.

Authors:  Shunji Nakatake; Yusuke Murakami; Yasuhiro Ikeda; Noriko Morioka; Takashi Tachibana; Kohta Fujiwara; Noriko Yoshida; Shoji Notomi; Toshio Hisatomi; Shigeo Yoshida; Tatsuro Ishibashi; Yusaku Nakabeppu; Koh-Hei Sonoda
Journal:  JCI Insight       Date:  2016-09-22

8.  Carnosic Acid Protects Mitochondria of Human Neuroblastoma SH-SY5Y Cells Exposed to Paraquat Through Activation of the Nrf2/HO-1Axis.

Authors:  Marcos Roberto de Oliveira; Alessandra Peres; Gustavo Costa Ferreira; Patrícia Fernanda Schuck; Clarissa S Gama; Simone Morelo Dal Bosco
Journal:  Mol Neurobiol       Date:  2016-09-29       Impact factor: 5.590

9.  Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral Therapy.

Authors:  Alexander J Gill; Colleen E Kovacsics; Patricia J Vance; Ronald G Collman; Dennis L Kolson
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

10.  Dimethyl Fumarate Limits Neuroinflammation and Oxidative Stress and Improves Cognitive Impairment After Polymicrobial Sepsis.

Authors:  Graciela Freitas Zarbato; Mariana Pereira de Souza Goldim; Amanda Della Giustina; Lucinéia Gainski Danielski; Khiany Mathias; Drielly Florentino; Aloir Neri de Oliveira Junior; Naiana da Rosa; Ana Olivia Laurentino; Taina Trombetta; Maria Luiza Gomes; Amanda Valnier Steckert; Ana Paula Moreira; Patricia Fernanda Schuck; Jucelia Jeremias Fortunato; Tatiana Barichello; Fabricia Petronilho
Journal:  Neurotox Res       Date:  2018-04-30       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.